Duyuru • Jan 01
Phase Holographic Imaging Announces Resignation of Mats Lundwall as Director, Effective December 30, 2025 Phase Holographic Imaging announced that Mats Lundwall, at his own request, has resigned from his position on the company's Board of Directors, effective December 30, 2025. Duyuru • Sep 26
Phase Holographic Imaging PHI AB (publ) to Report First Half, 2026 Results on Dec 19, 2025 Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2026 results on Dec 19, 2025 Duyuru • Aug 28
Phase Holographic Imaging PHI AB (publ) to Report Q1, 2026 Results on Sep 26, 2025 Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2026 results on Sep 26, 2025 Duyuru • Jun 26
Phase Holographic Imaging Phi AB (Publ) Announces Executive and Board Appointments, Effective from 1 July 2025 Phase Holographic Imaging PHI AB (publ) announced appointment of Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for company's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities. Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025. Duyuru • May 28
Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2025 Results on Jun 26, 2025 Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2025 results on Jun 26, 2025 Duyuru • May 23
Phase Holographic Imaging Phi AB (publ) Revises Revenue Guidance for Fiscal Year Ended on April 30, 2025 Phase Holographic Imaging PHI AB (publ) revised revenue guidance for Fiscal Year ended on April 30, 2025. For the period, the company expects total sales to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024. Duyuru • Mar 12
Phase Holographic Imaging Announces Next Generation HoloMonitor Phase Holographic Imaging (PHI) announced that the next generation of PHI's live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internationally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. The HoloMonitor CellSync marks the first in a series of models, with the long-term goal of delivering a clinical-grade product designed to set a new standard for automated quality control in cell and gene therapy manufacturing. The series is expected to include the latest developments in image processing and artificial intelligence. Manufactured by production partner in accordance with ISO 9001 standards, the HoloMonitor CellSync builds on the success of its predecessor, offering non-invasive, real-time imaging of live cells. It incorporates the latest advancements in PHI's core imaging technology, including an updated camera module and enhanced automated cell segmentation, which has been developed over the past two years. Duyuru • Feb 11
Phase Holographic Imaging Announces CEO Changes Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company's clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead. Anders will step down immediately and assist with the transition. Ivan Jurkovic, PHI board member and Altium group CFO, will serve as the acting CEO of PHI during the recruitment process. In his current technology developer role, PHI's founding board member and former CEO, Peter Egelberg, will assist in product development and technical matters. Ivan Jurkovic (Board member, born 1984) is an experienced financial executive with experience in the pharmaceutical industry, beverage industry and IT industry. Mr. Jurkovic currently holds the position of Chief Financial Officer at Altium SA. As part of his role at Altium, Mr. Jurkovic is responsible for Altium's financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth. Duyuru • Nov 20
Phase Holographic Imaging PHI AB (publ) to Report First Half, 2025 Results on Dec 19, 2024 Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2025 results on Dec 19, 2024 Duyuru • Nov 14
Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million. Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 35,729,342
Price\Range: SEK 1.8
Transaction Features: Rights Offering Duyuru • Oct 17
Phase Holographic Imaging Announces CEO Changes, Effective November 1, 2024 The board of Phase Holographic Imaging (PHI) has appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson. Starting November 1, 2024, Anders Månsson will succeed Patrik Eschricht as CEO of PHI. Månsson brings over 25 years of experience in the international Health & Life Sciences field, having held senior-level positions in both large multinationals and smaller biotech companies. Most recently, he served as CEO of Oncoinvent ASA, and he has also held numerous leadership roles, including CEO, Chairman, and Board Member positions. He is currently a board member of EQL Pharma AB and a Partner and Board Member at Immetric AB. Månsson's previous roles also include CEO of LIDDS AB, the biopharmaceutical company RhoVac AB, and stem cell research-based company Amniotics AB. He studied for an Executive MBA at Business School Lausanne, Switzerland. As CEO of PHI, Anders will be responsible for driving the company's future development, with a particular focus on R&D, product development, and establishing PHI as a leader in non-invasive cell quality control technologies. Duyuru • Jul 24
Phase Holographic Imaging PHI AB (publ) to Report Q3, 2025 Results on Aug 19, 2024 Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2025 results on Aug 19, 2024 Duyuru • Jul 22
Phase Holographic Imaging PHI AB (publ) Announces Resignation of Leland Foster as Board Member Phase Holographic Imaging PHI AB (publ) announced resignation of Leland Foster as board member. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments effective from July 22, 2024. Leland Foster, elected board member in 2012, has been a pivotal figure on PHI's board, providing invaluable guidance and insight drawn from his extensive experience in the industry. His contributions have been instrumental in steering the company towards innovation and growth. Duyuru • Jun 27
Phase Holographic Imaging PHI AB (publ) to Report Q1, 2025 Results on Sep 16, 2024 Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2025 results on Sep 16, 2024 Duyuru • Mar 27
Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2024 Results on Jun 26, 2024 Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2024 results on Jun 26, 2024 Duyuru • Mar 14
Phase Holographic Imaging PHI AB (Publ) Appoints Ivan Jurkovic as Ordinary Board Member Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting. The extraordinary general meeting resolved that the board of directors shall consist of six (6) ordinary board members, without deputy board members. For the period until the next annual general meeting, the general meeting resolved to elect Ivan Jurkovic as ordinary board member. Ivan Jurkovic, born in 1984, is an experienced financial business executive with experience from the pharmaceutical, beverage and IT industries. Jurkovic currently holds the position of Chief Financial Officer of Altium S.A. Within the scope of his assignment at Altium S.A., Jurkovic is responsible for the financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth. Duyuru • Jan 31
Phase Holographic Imaging PHI AB (publ) to Report Q3, 2024 Results on Mar 27, 2024 Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2024 results on Mar 27, 2024 Reported Earnings • Dec 21
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr1.23m (down 55% from 2Q 2023). Net loss: kr5.38m (loss widened 1.3% from 2Q 2023). Duyuru • Sep 21
Phase Holographic Imaging PHI AB (publ) to Report First Half, 2024 Results on Dec 21, 2023 Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2024 results on Dec 21, 2023 Reported Earnings • Sep 20
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr2.73m (up 34% from 1Q 2023). Net loss: kr4.30m (loss narrowed 25% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Duyuru • Sep 17
Phase Holographic Imaging PHI AB (publ) to Report Q1, 2024 Results on Sep 20, 2023 Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2024 results on Sep 20, 2023 Duyuru • Jul 04
European Patent Office Intends to Grant Phase Holographic Imaging AB Patent on Synthetic Antibodies Phase Holographic Imaging AB (PHI) announces that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies. The patent application "EP329447 Molecularly Imprinted Polymers" was submitted by PHI together with Germany's federal institute for materials research (BAM). PHI's corresponding patents concerning synthetic antibodies in the US and Japan were granted in 2020 and 2022, respectively. In spring 2023, PHI established the subsidiary PHI MIPS AB to house the synthetic antibody patent family and facilitate its business potential for the GlycoImaging project's outcome. Duyuru • Jun 27
Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023 Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023. Reported Earnings • Jun 27
Full year 2023 earnings released: kr1.13 loss per share (vs kr1.76 loss in FY 2022) Full year 2023 results: kr1.13 loss per share (improved from kr1.76 loss in FY 2022). Revenue: kr9.90m (up 21% from FY 2022). Net loss: kr23.2m (loss narrowed 8.7% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Duyuru • May 25
Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2023 Results on Jun 23, 2023 Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2023 results on Jun 23, 2023 Duyuru • May 10
Phase Holographic Imaging Phi AB (Publ) Elects Goran Dubravcic Elected as A New Member of the Board Phase Holographic Imaging Phi AB (Publ) announced that Goran Dubravcic elected as a new member of the Board. The newly elected board member Goran Dubravcic is the CEO of Altium SA, which currently owns 11.8% of the shares in the Company. Recent Insider Transactions Derivative • May 08
Director exercised options to buy kr105k worth of stock. On the 2nd of May, Leland Foster exercised options to buy 17k shares at a strike price of around kr3.78, costing a total of kr63k. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. Leland currently holds less than 1% of total shares outstanding. This was the only transaction from an insider over the last 12 months. Reported Earnings • Mar 30
Third quarter 2023 earnings released: kr0.22 loss per share (vs kr0.47 loss in 3Q 2022) Third quarter 2023 results: kr0.22 loss per share (improved from kr0.47 loss in 3Q 2022). Revenue: kr3.26m (up 19% from 3Q 2022). Net loss: kr4.41m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 22
Second quarter 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in 2Q 2022) Second quarter 2023 results: kr0.26 loss per share. Revenue: kr2.73m (up 50% from 2Q 2022). Net loss: kr5.30m (loss widened 36% from 2Q 2022). Duyuru • Dec 21
Phase Holographic Imaging PHI AB (publ) to Report Q3, 2023 Results on Mar 30, 2023 Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2023 results on Mar 30, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 30
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr2.04m (down 14% from 1Q 2022). Net loss: kr5.75m (loss widened 29% from 1Q 2022). Duyuru • Sep 30
Phase Holographic Imaging PHI AB (publ) to Report First Half, 2023 Results on Dec 21, 2022 Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2023 results on Dec 21, 2022 Duyuru • Sep 29
Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022 Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022. Agenda: Annual General Meeting. Reported Earnings • Jun 30
Full year 2022 earnings released: kr1.76 loss per share (vs kr1.63 loss in FY 2021) Full year 2022 results: kr1.76 loss per share (down from kr1.63 loss in FY 2021). Revenue: kr8.17m (up 125% from FY 2021). Net loss: kr25.4m (loss widened 8.0% from FY 2021). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Duyuru • Jun 29
Phase Holographic Imaging PHI AB (publ) to Report Q1, 2023 Results on Sep 29, 2022 Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2023 results on Sep 29, 2022 Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Jan 20
Phase Holographic Imaging Introduces Non-Invasive Fluorescence Units Phase Holographic Imaging (PHI) is currently preparing fluorescence units for its first users. The HoloMonitor add-on fluorescence unit enables medical research laboratories to analyze the all-important genetic activity of individual cells as they multiply in a cell incubator - without the detrimental effects associated with conventional fluorescence microscopy. Until January 20, 2022, researchers had no choice but to harm their valuable cells each time they were imaged. However, most of the fluorescence images during an experiment are taken to track cell movement, not to observe the much slower genetic changes. The combination of imaging techniques allows HoloMonitor to track cell movement using frequent but harmless holographic imaging rather than harmful fluorescence imaging. This unique ability leads to a dramatic reduction of the number of required fluorescence images, which allows HoloMonitor users to minimize or eliminate the undesired toxic effects when characterizing individual cells and their genetic activity. The result is more cost-effective and reliable research outcomes. Reported Earnings • Dec 30
Second quarter 2022 earnings: Revenues in line with analyst expectations Second quarter 2022 results: Revenue: kr1.82m (up 120% from 2Q 2021). Net loss: kr3.90m (loss narrowed 18% from 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 2% per year. Reported Earnings • Sep 30
First quarter 2022 earnings released The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: kr2.37m (up kr2.24m from 1Q 2021). Net loss: kr4.47m (loss narrowed 30% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. Reported Earnings • Jun 27
Full year 2021 earnings released: kr1.63 loss per share (vs kr1.83 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: kr3.64m (down 4.4% from FY 2020). Net loss: kr23.5m (loss narrowed 11% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 19
Third quarter 2021 earnings released: kr0.38 loss per share (vs kr0.41 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: kr770.0k (down 56% from 3Q 2020). Net loss: kr5.53m (loss narrowed 5.6% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 23
New 90-day low: kr22.80 The company is down 14% from its price of kr26.40 on 24 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 26
New 90-day low: kr23.65 The company is down 15% from its price of kr27.90 on 27 October 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period. Duyuru • Dec 15
Phase Holographic Imaging PHI AB (publ) to Report Q3, 2021 Results on Mar 16, 2021 Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2021 results on Mar 16, 2021 Is New 90 Day High Low • Dec 11
New 90-day low: kr25.25 The company is down 28% from its price of kr34.95 on 11 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. Is New 90 Day High Low • Nov 23
New 90-day low: kr27.25 The company is down 24% from its price of kr35.95 on 25 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. Duyuru • Nov 01
Phase Holographic Imaging PHI AB (publ) to Report Q2, 2021 Results on Dec 14, 2020 Phase Holographic Imaging PHI AB (publ) announced that they will report Q2, 2021 results on Dec 14, 2020 Is New 90 Day High Low • Oct 19
New 90-day low: kr28.65 The company is down 14% from its price of kr33.20 on 20 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 11% over the same period. Is New 90 Day High Low • Oct 02
New 90-day low: kr28.70 The company is down 13% from its price of kr33.00 on 03 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period. Reported Earnings • Sep 29
First quarter earnings released Over the last 12 months the company has reported total losses of kr25.6m, largely unchanged from the prior year. Total revenue was kr3.34m over the last 12 months, down 23% from the prior year. Duyuru • Aug 29
Phase Holographic Imaging PHI AB (publ) to Report First Half, 2021 Results on Sep 28, 2020 Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2021 results on Sep 28, 2020 Duyuru • Jul 26
Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2020 Final Results on Sep 01, 2020 Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2020 final results on Sep 01, 2020 